LUKANG PHARMACEUTICAL

STRIVING TO DEVELOP FOR 50 YEARS CARING FOR HUMAN HEALTH
NEWS CENTER
LATEST NEWS
Date:2018-06-21
Lukang Pharma and Cuba CIGB have successfully Signed Class I Innovative Drug Research and Development Project


Recently, Shandong Lukang Pharmaceutical Co., Ltd. and the Center for Genetic Engineering and Biotechnology (CIGB) of Cuba held a signing ceremony for Class I Innovative Drug CIGB-814 in Lukang FDF Industrial Park. President and General Manager Peng Xin and Cuba CIGB President Eulogio, on behalf of each Party, signed the contract.

CIGB is the most advanced biotechnology center in Cuba and is affiliated with the Cuban Biotech and Pharmaceutical Industry Group. Lukang has established a joint venture with Cuba’s CIGB in 2014 and has conducted in-depth cooperation on the basis of mutual trust and conducted Class I innovative drug CIGB-814 project cooperation. CIGB-814 products are used for the treatment of rheumatoid arthritis (RA). This product has very outstanding advantages compared with the existing international biological drugs for the treatment of RA: (1)Its side effect is small, not causing systemic infection, and it is not necessary to change the drugs at regulated period; (2)The total efficacy rate of biologics treating RA is about 50%, there is no significant efficacy for the other 50% patients, but the efficacy of CIGB-814 reached about 100% with specific selectivity for patients;(3)It does not affect the immune system of patients; (4)The dose is small (1mg), the total cost of cure is much lower than similar products.
 


 
After the signing the project, Lukang Pharma vice general manager Liu Songqiang communicated with CIGB-Heber general manager Rolando Paez on the project technology transfer and following-up work promotion, as well as deep communication on the cooperation in joint R&D platform of Chinese-Cuba Biotechnological products. President and General Manager Peng Xin and Cuba CIGB President Eulogio, on behalf of each Party, signed the “Memorandum of Understanding on Establishing a Joint R&D Platform for Chinese-Cuba Biotechnology Products”. The joint R&D platform was built at Lukang Hi-tech Zone Biotechnology Industrial Park, high-end pharmaceutical products such as vaccines, peptides, and gene medicines will be introduced through the CIGB which will bring l expand the broader cooperation space between Lukang and CIGB.

signing ceremony, President and General Manager Peng Xin introduced the Lukang’s profile in detail for Cuban guests, and showed them to tour the Lukang High-tech Zone Biotechnology Industrial Park and Zoucheng Bio-pharmaceutical Circular Economy Industrial Park. The Cuban guests highly praised the development strategy of Lukang and expressed a full confidence in the cooperation between the two parties.

SHARE WITH OTHERS